Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
'Every Call From Home Is About Safety': Indian Medical Students In Iran Describe Life Amid Protests
Consumer Connect: 'Homebuyers Must Urge Governor To Junk MOFA Amendment,' Says Expert
Global Student Mobility To Hit 8.5 Million By 2030 As Study Choices Turn Outcome-Driven
AUS vs ENG, 5th Ashes Test: Michael Neser's Spectacular Catch Ends Joe Root's Stunning Innings Of 160 Runs; VIDEO
